Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics will host an in-person and virtual R&D Day on October 14, 2025 at 8:00 a.m. ET, with a live webcast available on the Investors Events page. The accompanying company presentation is furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The information in Item 7.01 and Exhibit 99.1 is not deemed “filed” under the Exchange Act or Securities Act, except if expressly incorporated by reference.
On 30 June 2025, Aclaris Therapeutics, Inc. (Nasdaq: ACRS) filed an 8-K solely to furnish an updated corporate overview presentation (Exhibit 99.1) under Item 7.01 – Regulation FD Disclosure. The deck has been posted to the company’s website and is not deemed “filed” for Exchange Act liability or for incorporation by reference. No financial results, strategic transactions, or operational updates were disclosed. All other sections, including Item 9.01, merely list the exhibit numbers, and the filing was signed by CFO Kevin Balthaser.